This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Celgene Corporation. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Te-chen Tzeng: Innovator in Combination Therapies
Introduction
Te-chen Tzeng is a notable inventor based in Shrewsbury, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of combination therapies. His innovative work focuses on treating diseases responsive to the inhibition of PDE4.
Latest Patents
Te-chen Tzeng holds a patent for "Combination therapies comprising apremilast and Tyk2 inhibitors." This patent outlines methods for treating diseases and disorders by administering apremilast alongside a Tyk2 inhibitor. Additionally, it includes pharmaceutical compositions that combine these two components.
Career Highlights
Te-chen Tzeng is associated with Celgene Corporation, a leading biopharmaceutical company. His work at Celgene has been instrumental in advancing therapeutic options for patients with various conditions.
Collaborations
Te-chen has collaborated with notable colleagues, including Mary Adams and Robert Plenge. These partnerships have fostered a collaborative environment that enhances innovation and research.
Conclusion
Te-chen Tzeng's contributions to the field of combination therapies exemplify the impact of innovative thinking in pharmaceuticals. His work continues to pave the way for new treatment options that can improve patient outcomes.